All
UV-filtering contact lenses not protective
May 1st 2005The recent influx of contact lenses containing ultraviolet (UV) filters has prompted some patients to inquire about using these as protection after PUVA therapy, rather than coated prescription glasses, sunglasses or UV opaque protective goggles. But as Suliman Otman, M.D., M.S., a clinical research fellow at the Welsh Institute of Dermatology at Cardiff University, England, discovered, UV-blocking contact lenses are not suitable eye protection for people receiving Psoralen in combination with UVA light.
Can CME, experience offset doctors' age-related decline?
May 1st 2005National report — Does practice make perfect? A recent Harvard Medical School review suggests that as physicians age, the quality of care they provide decreases — the plethora of continuing medical education (CME) options available and the presumed benefits of wisdom notwithstanding.
Emergencies: Be prepared for inevitable
May 1st 2005New Orleans — Whether it is serious intraoperative bleeding, the presence of a life-threatening disease or a lethal drug reaction, the dermatologist's office should be prepared for the emergent crisis that can happen at any time and anywhere, Glenn D. Goldman, M.D., says.
'I am importing cheaper medications from Canada. How can I be in trouble?'
May 1st 2005There is still a natural desire to get the same medications from a cheaper source. Dr. Sue turned to Canada. Other physicians have turned to Europe and South America. But whatever the source, Dr. Sue's actions are illegal.
Overuse of black box warnings is scare tactic
May 1st 2005As the Vioxx/Celebrex scandal lays waste to the American healthcare landscape as we know it, the U.S. Food and Drug Administration (FDA) finds itself under relentless pressure to get things right. Congress is demanding more stringent safety standards and even threatening to create a new federal agency to take safety approvals and monitoring out of the FDA's hands.
Candida antifungal performs well in study
April 1st 2005An investigational topical antifungal product containing miconazole nitrate 0.25 percent in a petrolatum/zinc oxide barrier ointment base (Zimycan, Barrier Therapeutics) has demonstrated positive efficacy and safety results in a phase 3 study of the treatment of Candida diaper dermatitis.
Superficial peds infections abound
April 1st 2005New Orleans - In today's global, transient and sometimes overcrowded society, the spread of superficial cutaneous infections and infestations in children appears to be even more common than previously thought. International travel, immigration and foreign adoption have altered the typical distribution of some pediatric infections and infestations.
Advances aid treatment in pediatric dermatology
April 1st 2005There have been a number of important advances in pediatric dermatology, ranging from finding the optimal use for tissue adhesives to gaining a better understanding of general and local anesthetic use in the pediatric population and a greater appreciation for dermatologic surgeons' roles in treating vascular lesions and birthmarks.
Accurate, timely diagnosis of dermatoses in children critical
April 1st 2005New Orleans — Rare, life-threatening dermatoses are presenting in pediatric patients across the country, and some dermatologists are missing these critical diagnoses, according to Patricia Treadwell, M.D., professor of pediatrics, Riley Hospital for Children, Indianapolis.
Use of poly-L-lactic acid shows promise as treatment for lipodystrophic facial aging
April 1st 2005New Orleans — Initial clinical experience indicates injectable poly-L-lactic acid (Sculptra) can be used safely and effectively to achieve natural-appearing restoration of facial volume and contour in patients with age-related facial lipodystrophy, said Douglas Key, M.D., at the 63rd Annual Meeting of the American Academy of Dermatology (AAD) here.
Derm projects range of HA products will provide toolsfor lunchtime filling
April 1st 2005Boston — Although, for many patients, hyaluronic acid (HA) fillers have become the treatment of choice in the United States, Gary D. Monheit, M.D., says many questions remain: Can Hylaform (Inamed), Restylane (Q-Med) and Juvederm (LEA Derm) be improved to achieve more than a three- to six-month longevity? How will the fillers compare after more extensive head-to-head testing? And where will HA products ultimately fit in an armamentarium ranging from bovine collagen to polylactic acid?
Anidulafungin effective against ARMC
April 1st 2005Washington — Anidulafungin (Vicuron, Vicuron Pharmaceuticals Inc.), a new echinocandin presently being developed for the treatment of serious fungal infections, has been shown to be effective and well-tolerated in a large majority of patients who have azole-refractory mucosal candidiasis (ARMC), said Jennifer A. Schranz, M.D., in a presentation at the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy here.
Safe, effective hemostasis mandates
April 1st 2005New Orleans — Careful preoperative assessment to identify risk factors for increased perioperative bleeding, meticulous surgical technique to gain control of vessels and appropriate use of surgical adjuncts form the foundation for safe and effective hemostasis in dermatologic surgery, says David E. Kent, M.D., at the 63rd Annual Meeting of the American Academy of Dermatology.
Surgeon offers pearls for keloid tx
April 1st 2005Los Angeles — For stubborn keloids that do not respond to intralesional triamcinolone acetonide (Kenalog, Bristol-Myers Squibb), especially post-CABG sternal keloids, William V.R. Shellow, M.D., has successfully used methylprednisolone acetate (Depo-Medrol, Pharmacia & Upjohn), normally used by orthopedists for injecting joints.
Alternative treatments for alopecia areata
April 1st 2005Florence — Alopecia areata is a disease with important aesthetic implications that may affect the patient psychologically and socially, and treatment can be challenging, according to Ana Kaminsky, M.D., Ph.D., professor of dermatology, School of Medicine, University of Buenos Aires, Argentina.
Trial HSV-2 vaccines show promise
April 1st 2005Washington — Clinical studies have already demonstrated proof of concept for both prophylactic and therapeutic vaccines for herpes simplex virus (HSV)-2. Both types of HSV-2 vaccines are currently under development and the next few years should bring promising results, accordingto Lawrence R. Stanberry, M.D., Ph.D., chairman of the department of pediatrics and director of the Sealy Center for Vaccine Development at the University of Texas Medical Branch in Galveston.
Newer antibiotics potent weapons
April 1st 2005Aruba — Newer antibiotics with novel mechanisms of action offer activity against drug-resistant gram-positive organisms and are important additions to the dermatologist's therapeutic arsenal for treating cutaneous infections, according to Bernardo Vainrub, M.D., consultant in internal medicine and infectious diseases, Hospital de Clinicas, Caracas, Venezuela.